Abstract
Background and aims: Steno Diabetes Center North Denmark (SDCN) was established in 2018, with one of the initial programs being the same-day routine screening (SDS) for patients with diabetes. SDS was initially piloted at the Medical Department, Farsø, Aalborg University Hospital in 2019 and later in 2021 it became a part of the dailyroutine in all the hospitals in the North Denmark region. SDS ensures that patients get screened for all relevant complications of diabetes and providing patients the results same day. The primary aim of the study is to investigate the efectiveness of the SDS program by assessing its impact on outcome measures and comparing it to a matched control group that was not enrolled in the SDS program at the Department of Endocrinology, Aalborg, Aalborg University Hospital.
Materials and methods: Patients with type 1 diabetes (T1D) or type 2-diabetes (T2D) were included in the study if they have been enrolled in the SDS program for three years in a row during the period 2021-2023. The control group, referred to as non-SDS-group consist of patients who was not enrolled in the SDS program through the same period. Propensity Score Matching (PSM) was used to ensure comparability and adjust for confounding variables between the SDS group and non-SDS group. An unpaired t-test was then performed to analyze diferences between the groups across various outcomes including HbA1c, patient-reported experience measures (PREM), patientreported outcome measures (PROM), no-show rates, days seen at the hospital and out-of-pocket expenses for patients.
Results: A total of 2,216 patients were enrolled in this study with 1,753 in the SDS group and 464 in the non-SDS group. When performing the PSM and adjusting for confounding variables two groups were formed, each comprising 284 patients. Diferences in HbA1c was not observed between groups (p = 0.07). However, PREM and PROM indicated signifcant diferences in various questions between the groups (p <0.05). A declining rate of no-shows and fewer days at hospital was also observed in the study among SDS patients. Furthermore, there was a signifcant diference in out-of-pocket expenses for patients with diabetes.
Conclusion: In conclusion, the SDS program at SDCN has shown positive impacts on PREM and PROM questionnaires, reducing missed appointments (no show rate) and signifcant decreasing out-of-pocket costs for patients. These results highlight the efectiveness of SDS in enhancing patient care and resource utilization, advocating for continued implementation
Materials and methods: Patients with type 1 diabetes (T1D) or type 2-diabetes (T2D) were included in the study if they have been enrolled in the SDS program for three years in a row during the period 2021-2023. The control group, referred to as non-SDS-group consist of patients who was not enrolled in the SDS program through the same period. Propensity Score Matching (PSM) was used to ensure comparability and adjust for confounding variables between the SDS group and non-SDS group. An unpaired t-test was then performed to analyze diferences between the groups across various outcomes including HbA1c, patient-reported experience measures (PREM), patientreported outcome measures (PROM), no-show rates, days seen at the hospital and out-of-pocket expenses for patients.
Results: A total of 2,216 patients were enrolled in this study with 1,753 in the SDS group and 464 in the non-SDS group. When performing the PSM and adjusting for confounding variables two groups were formed, each comprising 284 patients. Diferences in HbA1c was not observed between groups (p = 0.07). However, PREM and PROM indicated signifcant diferences in various questions between the groups (p <0.05). A declining rate of no-shows and fewer days at hospital was also observed in the study among SDS patients. Furthermore, there was a signifcant diference in out-of-pocket expenses for patients with diabetes.
Conclusion: In conclusion, the SDS program at SDCN has shown positive impacts on PREM and PROM questionnaires, reducing missed appointments (no show rate) and signifcant decreasing out-of-pocket costs for patients. These results highlight the efectiveness of SDS in enhancing patient care and resource utilization, advocating for continued implementation
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetologia |
Vol/bind | 67 |
Udgave nummer | Suppl. 1 |
Sider (fra-til) | S403 |
ISSN | 0012-186X |
Status | Udgivet - 12 sep. 2024 |
Begivenhed | European Association for the Study of Diabetes (EASD) 60th Annual Meeting - IFEMA, Madrid, Spanien Varighed: 9 sep. 2024 → 13 sep. 2024 |
Konference
Konference | European Association for the Study of Diabetes (EASD) 60th Annual Meeting |
---|---|
Lokation | IFEMA |
Land/Område | Spanien |
By | Madrid |
Periode | 09/09/2024 → 13/09/2024 |